Anxiety Treatment in Maplewood, NJ

Anxiety is the body's ancient threat-response system firing at things that are not actually threats: a work meeting, a checking account balance, a small social interaction, or nothing identifiable at all. Physiologically, anxiety looks like racing heart, shallow breathing, muscle tension, stomach upset, restlessness, and a mind that cycles through worst-case scenarios. Cognitively, it looks like rumination — the same worry running on a loop for hours or days, resistant to logic. Behaviorally, it looks like avoidance — of places, people, decisions, and situations that might provoke the anxiety, which in turn shrinks the life around the illness.

About 19% of U.S. adults experience an anxiety disorder in any given year. Most never get treated, often because they've normalized it — “I've always been an anxious person,” “It runs in my family,” “I just need to push through.” The USPSTF now recommends screening all adults aged 19–64 for anxiety, because the gap between what's treatable and what's being treated is too large. The clinical distinction that matters is between ordinary anxiety (appropriate to the situation, finite, doesn't derail functioning) and an anxiety disorder (disproportionate to the actual risk, persistent, and causing real functional impact).

This page covers how we diagnose and treat the full family of anxiety disorders at our Maplewood office and over NJ-wide telehealth. The short version: first-line care is an SSRI combined with CBT or exposure therapy; benzodiazepines have a narrow role and a clear exit plan; most patients see meaningful improvement in 8–12 weeks.

Every new anxiety patient at our clinic starts with a 60–90-minute comprehensive evaluation. The clinical interview maps your symptoms against DSM-5-TR criteria for each anxiety disorder on the differential. The GAD-7 — a validated seven-item self-report screener — produces a severity score (0–21, with 10+ suggesting a probable anxiety disorder and 15+ suggesting severe). For social anxiety specifically, we use the Liebowitz Social Anxiety Scale; for panic, a structured panic-frequency record; for trauma-related anxiety, the PCL-5. Like the PHQ-9 in depression, these screeners are not diagnostic on their own; they anchor the conversation in shared data and give us a baseline to measure treatment response.

Several medical conditions mimic anxiety disorders closely enough that we screen for them at the initial visit. Hyperthyroidism produces a nearly identical syndrome — racing heart, sweating, tremor, insomnia, restlessness — and a TSH panel catches it. Cardiac arrhythmias, especially atrial fibrillation and supraventricular tachycardia, present with panic-like chest pressure and palpitations. Pheochromocytoma is rare but causes catecholamine surges that look like panic disorder. Caffeine intake — often underestimated — can produce full-blown anxiety physiology at doses above 400 mg/day. Some medications (decongestants, stimulants, bronchodilators, corticosteroids) cause anxiety as a side effect. We work through the differential before we commit to a psychiatric diagnosis.

We do prescribe benzodiazepines when they are clinically indicated. The typical use cases are: a 2–4-week bridge during the early phase of SSRI treatment while the SSRI reaches therapeutic effect; PRN use for specific predictable triggers (flying, MRI, medical procedures, one-off public-speaking event); or short-term treatment of acute situational anxiety following a specific life event. Less commonly, we continue long-standing benzodiazepine therapy for patients who were stabilized on it by a prior provider, after a careful review of risks and benefits and with an explicit plan about whether and when we would consider a taper.

What we do not do is renew benzodiazepine prescriptions indefinitely without conversation. Every benzodiazepine prescription carries a clinical rationale in the chart. We check the New Jersey Prescription Drug Monitoring Program (NJ PDMP) before every controlled-substance prescription — regulatory requirement and safety check — and flag patterns that suggest concerning use. If a structured taper is indicated, we build the taper schedule, support you through the 4–8-week process, and typically bring CBT and an SSRI online before or during the taper.

Several lifestyle interventions have real effect sizes for anxiety and compound the benefit of medication and therapy. Aerobic exercise three to five times per week produces consistent anxiety reduction with effect sizes in the range of mild SSRI response. Consistent sleep timing — same bedtime and wake time, including weekends — stabilizes the circadian architecture that anxiety disrupts. Caffeine is the single most underestimated anxiety driver; many patients normalize three to six cups of coffee per day and describe anxiety that disappears when we halve the caffeine intake. Alcohol reduces anxiety acutely but produces rebound anxiety the next day; for patients using alcohol as self-medication, treating the underlying anxiety usually reduces the drinking.

Breathing techniques have a legitimate physiologic basis — slow nasal breathing activates the parasympathetic response and measurably lowers heart rate and cortisol. Two of the most teachable protocols are box breathing (inhale 4, hold 4, exhale 4, hold 4) and 4-7-8 breathing (inhale 4, hold 7, exhale 8). Both produce a noticeable shift within 3–5 minutes of practice. They are not a substitute for treatment, but they are useful in-the-moment tools for ordinary spikes and a reasonable starting point while a first SSRI reaches full effect.

Mindfulness meditation has a growing evidence base for anxiety, particularly Mindfulness-Based Stress Reduction (MBSR) — an eight-week structured program. We recommend apps (Headspace, Insight Timer) to patients who want to start, and formal MBSR programs in the Newark and Morristown areas for patients who want structured group curriculum.

Anxiety is almost never a solo diagnosis. Roughly half of patients with an anxiety disorder also meet criteria for depression, and a meaningful fraction have ADHD, panic disorder, or a trauma history on top. Managing the full picture in one practice — rather than fragmenting it across specialists who don't talk — is the biggest structural advantage of the PMHNP model for comorbid patients. One plan, one record, one relationship.

When anxiety co-occurs with depression, an SSRI usually addresses both — sertraline, escitalopram, and venlafaxine have solid evidence across the anxiety-depression spectrum. When anxiety co-occurs with ADHD, the sequencing matters: stimulants can worsen anxiety in some patients, so we typically treat the anxiety first, stabilize it, and then layer a stimulant or non-stimulant for ADHD; sometimes a non-stimulant (atomoxetine, guanfacine) is the better ADHD choice in anxious patients. When anxiety co-occurs with panic disorder, the panic piece often drives the anxiety piece — successful panic treatment often resolves the residual generalized anxiety. When trauma is part of the picture, we screen for PTSD explicitly with the PCL-5 and refer to a trauma-focused therapist in parallel with pharmacotherapy.